HealthCare Global Enterprises Limited has made a regulatory disclosure under SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, specifically Regulation 30, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026.

The Nomination and Remuneration Committee of the Board of Directors approved the grant of Employee Stock Options (ESOPs) at its meeting held on November 5, 2026. The meeting commenced at 11:00 a.m. IST and concluded at 11:15 a.m. IST.

Key Details of ESOP Grant:

  • Number of Options Granted: 70,000 (Seventy Thousand) options
  • Scheme Name: HealthCare Global Enterprises Limited-Employee Stock Option Scheme, 2026 (HCG ESOS 2026)
  • Eligible Employees: Employees of the Company and its subsidiary company(ies) and associate company(ies), in India or outside India
  • Total Shares Covered: 70,000 (Seventy Thousand) shares
  • Conversion Terms: Each option converts into one equity share of face value ₹10 each fully paid-up upon exercise
  • Exercise Price: ₹495 per share
  • Vesting Period: Not applicable at grant stage. Options shall have vesting period determined by Committee with minimum 1 year and maximum 7 years from grant date
  • Exercise Period: Maximum 10 years from grant date, commencing after expiry of 6 years from grant date or upon change in control event, whichever is earlier
  • Change in Control Provision: If change in control occurs, grantee has 6 months from date of such event to exercise vested options. If change occurs before 1 year from grant date, exercise period commences only after expiry of 1 year from grant date

Current Status:

  • Options exercised: Not applicable
  • Money realized by exercise: Not applicable
  • Total shares from exercised options: Not applicable
  • Options lapsed: Not applicable
  • Variation of terms: Not applicable
  • Subsequent changes/cancellation: Not applicable
  • Diluted EPS impact: Not applicable

The significant terms of HCG ESOS 2026 are stated to be the same as disclosed under the postal ballot notice.

Financial Impact:

Financial impact not quantified in the disclosure. The grant represents potential future equity dilution of 70,000 shares upon full exercise of all options.

Compliance Information:

The disclosure was signed by Sunu Manuel, Company Secretary and Compliance Officer, on November 5, 2026, at 20:29:25 IST. The information is also available on the company's website at https://www.hcgoncology.com/.